Novartis Weighs Synergies, Spending And Tax Under Sandoz Review
‘We Believe The Generics Market Is Attractive,’ Novartis Says
Novartis gave further color during its Q3 earnings call on its plans to conduct a strategic review for its Sandoz business. The Street also had its say, following years of calls by investors for Novartis to weigh Sandoz’ future as part of the group.
